Covered recipient · General Payments record
GARY MICHAEL REISS
Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$2,560.11
134 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $2,560.11 | 134 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Laborie Medical Technologies Corp. | $599.77 | 7 |
| ABBVIE INC. | $466.57 | 54 |
| Takeda Pharmaceuticals U.S.A., Inc. | $295.76 | 18 |
| Medtronic, Inc. | $203.34 | 2 |
| Ardelyx, Inc. | $203.10 | 9 |
| AnX Robotica Corp | $156.36 | 1 |
| Phathom Pharmaceuticals, Inc. | $131.33 | 14 |
| Janssen Biotech, Inc. | $59.15 | 4 |
| Celltrion USA Inc. | $54.83 | 3 |
| GENZYME CORPORATION | $53.34 | 3 |
| Regeneron Healthcare Solutions, Inc. | $48.95 | 2 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $47.92 | 3 |
| Celgene Corporation | $39.72 | 2 |
| CONMED Corporation | $35.79 | 1 |
| FUJIFILM Healthcare Americas Corporation | $35.48 | 2 |
| Ipsen Biopharmaceuticals, Inc | $29.66 | 2 |
| Gilead Sciences, Inc. | $22.16 | 1 |
| IRONWOOD PHARMACEUTICALS, INC | $17.65 | 1 |
| Merck Sharp & Dohme LLC | $14.77 | 1 |
| PFIZER INC. | $14.20 | 1 |
| Intercept Pharmaceuticals, Inc. | $13.58 | 1 |
| Braintree Laboratories, Inc. | $13.50 | 1 |
| Organon Llc | $3.18 | 1 |
Page 3 of 3; records 101–134 of 134 matching records. This page contains 34 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
GARY MICHAEL REISS
NPI 1568666543 · CMS profile ID 25373
Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology
MARRERO, LA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–134 of 134 matching records. This page contains 34 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1568666543?year=2024&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- GARY MICHAEL REISS, NPI 1568666543, CMS profile ID 25373. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–134 of 134 matching records. This page contains 34 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1568666543?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). GARY MICHAEL REISS, NPI 1568666543, CMS profile ID 25373. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–134 of 134 matching records. This page contains 34 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1568666543?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- GARY MICHAEL REISS, NPI 1568666543, CMS profile ID 25373, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–134 of 134 matching records. This page contains 34 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1568666543?year=2024&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
134 matching records · $2,560.11 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–134 of 134.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $14.51 | 03/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105936554 | CMS |
| ABBVIE INC. | $5.54 | 03/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105936552 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $13.30 | 03/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1137661342 | CMS |
| ABBVIE INC. | $13.39 | 03/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105936550 | CMS |
| CONMED Corporation | $35.79 | 03/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1142400748 | CMS |
| Braintree Laboratories, Inc. | $13.50 | 03/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1125517257 | CMS |
| ABBVIE INC. | $16.15 | 03/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105936548 | CMS |
| Phathom Pharmaceuticals, Inc. | $15.67 | 03/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1151115435 | CMS |
| Ardelyx, Inc. | $24.97 | 02/28/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1146703618 | CMS |
| Laborie Medical Technologies Corp. | $84.60 | 02/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1154320574 | CMS |
| Laborie Medical Technologies Corp. | $90.64 | 02/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1154320584 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $15.86 | 02/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1137661340 | CMS |
| Phathom Pharmaceuticals, Inc. | $9.84 | 02/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1151115433 | CMS |
| Laborie Medical Technologies Corp. | $93.33 | 02/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1154320572 | CMS |
| ABBVIE INC. | $17.83 | 02/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105936546 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $16.36 | 02/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1137661338 | CMS |
| ABBVIE INC. | $3.34 | 02/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105936544 | CMS |
| ABBVIE INC. | $4.91 | 02/07/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105936542 | CMS |
| Ardelyx, Inc. | $22.25 | 02/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1146703616 | CMS |
| Phathom Pharmaceuticals, Inc. | $8.11 | 02/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1151115431 | CMS |
| ABBVIE INC. | $14.62 | 02/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105936540 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $24.14 | 02/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1137661336 | CMS |
| ABBVIE INC. | $2.56 | 01/29/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105936538 | CMS |
| ABBVIE INC. | $13.70 | 01/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105936534 | CMS |
| ABBVIE INC. | $2.90 | 01/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105936536 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $12.02 | 01/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1137661334 | CMS |
| ABBVIE INC. | $2.95 | 01/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105936532 | CMS |
| ABBVIE INC. | $16.88 | 01/17/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105936530 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $69.18 | 01/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1137661332 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $15.18 | 01/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1137661330 | CMS |
| Janssen Biotech, Inc. | $13.44 | 01/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078675948 | CMS |
| ABBVIE INC. | $13.75 | 01/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105936528 | CMS |
| ABBVIE INC. | $0.67 | 01/04/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105936524 | CMS |
| ABBVIE INC. | $0.90 | 01/04/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105936526 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $585,490.76 | 277 |
| PY2024 | Principal investigator | $1,428,217.32 | 288 |
| PY2023 | Recipient | $48.50 | 1 |
| PY2023 | Principal investigator | $1,178,528.96 | 493 |
| PY2022 | Recipient | $9,282.61 | 2 |
| PY2022 | Principal investigator | $1,335,502.11 | 758 |
| PY2021 | Principal investigator | $1,416,189.45 | 333 |
| PY2020 | Recipient | $9,786.69 | 1 |
| PY2020 | Principal investigator | $1,898,224.92 | 171 |
| PY2019 | Recipient | $2,269.77 | 1 |
| PY2019 | Principal investigator | $2,063,421.55 | 95 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
277 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,925.00 | 12/31/2025 | Non-covered Recipient Entity Tandem Clinical Research-Marrero Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220716166 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,589.00 | 12/31/2025 | Non-covered Recipient Entity Tandem Clinical Research-Marrero Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220716168 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,719.40 | 12/30/2025 | Non-covered Recipient Entity Tandem Clinical Research-Marrero Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220716174 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,626.00 | 12/26/2025 | Non-covered Recipient Entity Tandem Clinical Research-Marrero Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220716234 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,956.00 | 12/22/2025 | Non-covered Recipient Entity Tandem Clinical Research-Marrero Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220716164 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,613.00 | 12/22/2025 | Non-covered Recipient Entity Tandem Clinical Research-Marrero Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220716178 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,919.60 | 12/19/2025 | Non-covered Recipient Entity Tandem Clinical Research-Marrero Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220716170 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,719.40 | 12/19/2025 | Non-covered Recipient Entity Tandem Clinical Research-Marrero Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220716180 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,719.40 | 12/19/2025 | Non-covered Recipient Entity Tandem Clinical Research-Marrero Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220716184 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,579.40 | 12/19/2025 | Non-covered Recipient Entity Tandem Clinical Research-Marrero Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220716192 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,365.00 | 12/19/2025 | Non-covered Recipient Entity Tandem Clinical Research-Marrero Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220716230 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,238.86 | 12/19/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248254460 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $637.88 | 12/19/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248254465 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $250.00 | 12/19/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184279466 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 12/19/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184279468 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,527.00 | 12/18/2025 | Non-covered Recipient Entity Tandem Clinical Research-Marrero Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220716162 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,422.60 | 12/18/2025 | Non-covered Recipient Entity Tandem Clinical Research-Marrero Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220716172 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.64 | 12/17/2025 | Non-covered Recipient Entity Tandem Clinical Research-Marrero Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220716232 |
| Principal investigator 1 | Janssen Research & Development, LLC | $236.00 | 12/17/2025 | Non-covered Recipient Entity Tandem Intermediate Llc | A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) | No dispute reported | 06/30/2026 | 1175223933 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,058.00 | 12/17/2025 | Non-covered Recipient Entity Tandem Intermediate Llc | A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) | No dispute reported | 06/30/2026 | 1175223954 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,058.00 | 12/17/2025 | Non-covered Recipient Entity Tandem Intermediate Llc | A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) | No dispute reported | 06/30/2026 | 1175223977 |
| Principal investigator 1 | Janssen Research & Development, LLC | $236.00 | 12/17/2025 | Non-covered Recipient Entity Tandem Intermediate Llc | A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) | No dispute reported | 06/30/2026 | 1175224018 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,497.00 | 12/17/2025 | Non-covered Recipient Entity Tandem Intermediate Llc | A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) | No dispute reported | 06/30/2026 | 1175224034 |
| Principal investigator 1 | Janssen Research & Development, LLC | $236.00 | 12/17/2025 | Non-covered Recipient Entity Tandem Intermediate Llc | A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) | No dispute reported | 06/30/2026 | 1175224052 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,497.00 | 12/17/2025 | Non-covered Recipient Entity Tandem Intermediate Llc | A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) | No dispute reported | 06/30/2026 | 1175224088 |
| Principal investigator 1 | Janssen Research & Development, LLC | $236.00 | 12/17/2025 | Non-covered Recipient Entity Tandem Intermediate Llc | A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) | No dispute reported | 06/30/2026 | 1175224105 |
| Principal investigator 1 | Janssen Research & Development, LLC | $236.00 | 12/17/2025 | Non-covered Recipient Entity Tandem Intermediate Llc | A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) | No dispute reported | 06/30/2026 | 1175224114 |
| Principal investigator 1 | Janssen Research & Development, LLC | $236.00 | 12/17/2025 | Non-covered Recipient Entity Tandem Intermediate Llc | A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) | No dispute reported | 06/30/2026 | 1175224139 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $140.00 | 12/12/2025 | Non-covered Recipient Entity Tandem Clinical Research-Marrero Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220716182 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $980.00 | 12/12/2025 | Non-covered Recipient Entity Tandem Clinical Research-Marrero Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220716186 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $770.00 | 12/12/2025 | Non-covered Recipient Entity Tandem Clinical Research-Marrero Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220716188 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $10,920.00 | 12/12/2025 | Non-covered Recipient Entity Tandem Clinical Research-Marrero Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220716190 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $500.00 | 12/11/2025 | Non-covered Recipient Entity Tandem Clinical Research | A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). | No dispute reported | 06/30/2026 | 1176547187 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,917.89 | 12/11/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248253970 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $3,438.00 | 12/11/2025 | Non-covered Recipient Entity TANDEM INTERMEDIATE LLC | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure | No dispute reported | 06/30/2026 | 1244050502 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,300.00 | 12/11/2025 | Non-covered Recipient Entity TANDEM INTERMEDIATE LLC | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure | No dispute reported | 06/30/2026 | 1244050504 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $500.00 | 12/10/2025 | Non-covered Recipient Entity Tandem Clinical Research-Marrero Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220716176 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $222.75 | 12/04/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248253474 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,799.30 | 12/04/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184269595 |
| Principal investigator 1 | Senseonics, Incorporated | $87.75 | 12/04/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI, LLC | Senseonics CTP-0039 | No dispute reported | 06/30/2026 | 1249852999 |
| Principal investigator 1 | Senseonics, Incorporated | $400.00 | 12/04/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI, LLC | Senseonics CTP-0039 | No dispute reported | 06/30/2026 | 1249853001 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,238.86 | 11/25/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248252955 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 11/20/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184263381 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $299.70 | 11/20/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184263383 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $372.73 | 11/20/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184263385 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $78.30 | 11/20/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184263387 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $19.98 | 11/19/2025 | Non-covered Recipient Entity Tandem Clinical Research-Marrero Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220716236 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $36.50 | 11/19/2025 | Non-covered Recipient Entity Tandem Clinical Research-Marrero Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220716238 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $15,550.00 | 11/14/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA | No dispute reported | 06/30/2026 | 1192135127 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $300.81 | 11/14/2025 | Non-covered Recipient Entity TANDEM INTERMEDIATE LLC | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure | No dispute reported | 06/30/2026 | 1244050500 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $100.00 | 11/07/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248252512 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,336.65 | 11/07/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184258073 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $200.00 | 11/07/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184258081 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $485.00 | 11/07/2025 | Non-covered Recipient Entity TANDEM INTERMEDIATE LLC | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure | No dispute reported | 06/30/2026 | 1244050496 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $5,063.00 | 11/07/2025 | Non-covered Recipient Entity TANDEM INTERMEDIATE LLC | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure | No dispute reported | 06/30/2026 | 1244050498 |
| Principal investigator 1 | Janssen Research & Development, LLC | $236.00 | 11/03/2025 | Non-covered Recipient Entity Tandem Intermediate Llc | A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) | No dispute reported | 06/30/2026 | 1175223919 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,809.00 | 10/28/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA | No dispute reported | 06/30/2026 | 1192127777 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $182.50 | 10/27/2025 | Non-covered Recipient Entity Tandem Clinical Research-Marrero Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220716194 |
| Principal investigator 1 | Senseonics, Incorporated | $87.75 | 10/23/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI, LLC | Senseonics CTP-0039 | No dispute reported | 06/30/2026 | 1249852991 |
| Principal investigator 1 | Senseonics, Incorporated | $2,267.81 | 10/23/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI, LLC | Senseonics CTP-0039 | No dispute reported | 06/30/2026 | 1249852993 |
| Principal investigator 1 | Senseonics, Incorporated | $87.75 | 10/23/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI, LLC | Senseonics CTP-0039 | No dispute reported | 06/30/2026 | 1249852995 |
| Principal investigator 1 | Senseonics, Incorporated | $87.75 | 10/23/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI, LLC | Senseonics CTP-0039 | No dispute reported | 06/30/2026 | 1249852997 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,213.84 | 10/17/2025 | Non-covered Recipient Entity Tandem Clinical Research-Marrero Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220716228 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $222.75 | 10/17/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248251652 |
| Principal investigator 1 | Chugai Pharmaceutical Co., Ltd. | $3,250.00 | 10/16/2025 | Non-covered Recipient Entity Tandem Clinical Research LLC | A PHASE I, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND BIOMARKERS OF DONQ52 IN CELIAC DISEASE PATIENTS | No dispute reported | 06/30/2026 | 1211661205 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $300.00 | 10/16/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184250937 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,336.65 | 10/03/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184244917 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $3,438.00 | 10/03/2025 | Non-covered Recipient Entity TANDEM INTERMEDIATE LLC | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure | No dispute reported | 06/30/2026 | 1244050494 |
| Principal investigator 1 | Senseonics, Incorporated | $87.75 | 10/02/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI, LLC | Senseonics CTP-0039 | No dispute reported | 06/30/2026 | 1249852983 |
| Principal investigator 1 | Senseonics, Incorporated | $87.75 | 10/02/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI, LLC | Senseonics CTP-0039 | No dispute reported | 06/30/2026 | 1249852985 |
| Principal investigator 1 | Senseonics, Incorporated | $2,267.81 | 10/02/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI, LLC | Senseonics CTP-0039 | No dispute reported | 06/30/2026 | 1249852987 |
| Principal investigator 1 | Senseonics, Incorporated | $87.75 | 10/02/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI, LLC | Senseonics CTP-0039 | No dispute reported | 06/30/2026 | 1249852989 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $116.60 | 09/24/2025 | Non-covered Recipient Entity Tandem Clinical Research-Marrero Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220716154 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $99.90 | 09/24/2025 | Non-covered Recipient Entity Tandem Clinical Research-Marrero Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220716156 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $730.00 | 09/24/2025 | Non-covered Recipient Entity Tandem Clinical Research-Marrero Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220716158 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $10.00 | 09/24/2025 | Non-covered Recipient Entity Tandem Clinical Research-Marrero Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220716160 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $139.92 | 09/24/2025 | Non-covered Recipient Entity Tandem Clinical Research-Marrero Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220716220 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $239.76 | 09/24/2025 | Non-covered Recipient Entity Tandem Clinical Research-Marrero Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220716222 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,095.00 | 09/24/2025 | Non-covered Recipient Entity Tandem Clinical Research-Marrero Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220716224 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6.00 | 09/24/2025 | Non-covered Recipient Entity Tandem Clinical Research-Marrero Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220716226 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $997.50 | 09/23/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184241830 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,809.00 | 09/16/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA | No dispute reported | 06/30/2026 | 1192138491 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,917.89 | 09/12/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248249973 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $7,796.65 | 09/12/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184236830 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $10,928.25 | 08/28/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248249279 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $7,290.00 | 08/26/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184230531 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $200.00 | 08/26/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184230533 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $100.00 | 08/26/2025 | Non-covered Recipient Entity TANDEM INTERMEDIATE LLC | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure | No dispute reported | 06/30/2026 | 1244050492 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,000.00 | 08/22/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA | No dispute reported | 06/30/2026 | 1192127760 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,314.91 | 08/22/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248248996 |
| Principal investigator 1 | Senseonics, Incorporated | $87.75 | 08/21/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI, LLC | Senseonics CTP-0039 | No dispute reported | 06/30/2026 | 1249852977 |
| Principal investigator 1 | Senseonics, Incorporated | $2,267.81 | 08/21/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI, LLC | Senseonics CTP-0039 | No dispute reported | 06/30/2026 | 1249852979 |
| Principal investigator 1 | Senseonics, Incorporated | $87.75 | 08/21/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI, LLC | Senseonics CTP-0039 | No dispute reported | 06/30/2026 | 1249852981 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,235.25 | 08/18/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248248724 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,235.25 | 08/18/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248248727 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,755.00 | 08/18/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248248731 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,739.77 | 08/12/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192123545 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $540.00 | 08/01/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192127732 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $67.50 | 08/01/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192129734 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $100.00 | 08/01/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192135096 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $15,990.21 | 07/31/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248247772 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,873.13 | 07/31/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248247881 |
| Principal investigator 1 | Senseonics, Incorporated | $87.75 | 07/31/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI, LLC | Senseonics CTP-0039 | No dispute reported | 06/30/2026 | 1249852973 |
| Principal investigator 1 | Senseonics, Incorporated | $87.75 | 07/31/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI, LLC | Senseonics CTP-0039 | No dispute reported | 06/30/2026 | 1249852975 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $222.75 | 07/30/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248247634 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $219.00 | 07/28/2025 | Non-covered Recipient Entity Tandem Clinical Research-Marrero Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220716152 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $100.00 | 07/24/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192135089 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $270.00 | 07/24/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192135111 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,235.25 | 07/22/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248247406 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,435.80 | 07/22/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184217979 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $300.00 | 07/22/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184217983 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $2,500.00 | 07/22/2025 | Non-covered Recipient Entity TANDEM INTERMEDIATE LLC | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure | No dispute reported | 06/30/2026 | 1244050486 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $2,000.00 | 07/22/2025 | Non-covered Recipient Entity TANDEM INTERMEDIATE LLC | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure | No dispute reported | 06/30/2026 | 1244050488 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $10,000.00 | 07/22/2025 | Non-covered Recipient Entity TANDEM INTERMEDIATE LLC | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure | No dispute reported | 06/30/2026 | 1244050490 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $87.19 | 07/17/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248247138 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $1,489.65 | 07/16/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH | A Phase 2b3 Randomized, Double blind, Placebo controlled Study to Evaluate the Safety and Efficacy of Cotadutide in Participants with Non cirrhotic Non alcoholic Steatohepatitis with Fibrosis | No dispute reported | 06/30/2026 | 1185551808 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $8,050.00 | 07/16/2025 | Non-covered Recipient Entity Tandem Clinical Research-Marrero Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220716150 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,809.00 | 07/16/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA | No dispute reported | 06/30/2026 | 1192127753 |
| Principal investigator 1 | Bausch Health US, LLC | $1,722.40 | 07/14/2025 | Non-covered Recipient Entity Tandem Clinical Research GI, LLC | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis | No dispute reported | 06/30/2026 | 1224846245 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,755.74 | 07/14/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192127738 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $7,215.75 | 07/09/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248246706 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $10,800.00 | 06/30/2025 | Non-covered Recipient Entity Tandem Clinical Research-Marrero Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220716142 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,000.00 | 06/26/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA | No dispute reported | 06/30/2026 | 1192138496 |
| Principal investigator 1 | Senseonics, Incorporated | $2,267.81 | 06/26/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI, LLC | Senseonics CTP-0039 | No dispute reported | 06/30/2026 | 1249852967 |
| Principal investigator 1 | Senseonics, Incorporated | $2,267.81 | 06/26/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI, LLC | Senseonics CTP-0039 | No dispute reported | 06/30/2026 | 1249852969 |
| Principal investigator 1 | Senseonics, Incorporated | $2,267.81 | 06/26/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI, LLC | Senseonics CTP-0039 | No dispute reported | 06/30/2026 | 1249852971 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,025.13 | 06/24/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA | No dispute reported | 06/30/2026 | 1192129747 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $993.01 | 06/24/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA | No dispute reported | 06/30/2026 | 1192135103 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,235.25 | 06/24/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248246065 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,238.86 | 06/19/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248245815 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $222.75 | 06/19/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248245823 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,235.25 | 06/18/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248245733 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,403.00 | 06/16/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248245659 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,545.18 | 06/12/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192123555 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,000.00 | 06/12/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184206651 |
| Principal investigator 1 | Bausch Health US, LLC | $7,025.53 | 06/11/2025 | Non-covered Recipient Entity Tandem Clinical Research GI, LLC | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis | No dispute reported | 06/30/2026 | 1224846252 |
| Principal investigator 1 | Janssen Research & Development, LLC | $315.00 | 06/11/2025 | Non-covered Recipient Entity Tandem Intermediate Llc | A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) | No dispute reported | 06/30/2026 | 1175224131 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,255.57 | 06/05/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248244957 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,184.75 | 06/05/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184204451 |
| Principal investigator 1 | Senseonics, Incorporated | $87.75 | 05/29/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI, LLC | Senseonics CTP-0039 | No dispute reported | 06/30/2026 | 1249852955 |
| Principal investigator 1 | Senseonics, Incorporated | $87.75 | 05/29/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI, LLC | Senseonics CTP-0039 | No dispute reported | 06/30/2026 | 1249852957 |
| Principal investigator 1 | Senseonics, Incorporated | $87.75 | 05/29/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI, LLC | Senseonics CTP-0039 | No dispute reported | 06/30/2026 | 1249852959 |
| Principal investigator 1 | Senseonics, Incorporated | $2,267.81 | 05/29/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI, LLC | Senseonics CTP-0039 | No dispute reported | 06/30/2026 | 1249852961 |
| Principal investigator 1 | Senseonics, Incorporated | $87.75 | 05/29/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI, LLC | Senseonics CTP-0039 | No dispute reported | 06/30/2026 | 1249852963 |
| Principal investigator 1 | Senseonics, Incorporated | $87.75 | 05/29/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI, LLC | Senseonics CTP-0039 | No dispute reported | 06/30/2026 | 1249852965 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $270.00 | 05/28/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192129710 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,600.50 | 05/28/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184199091 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 05/28/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184199095 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $99.90 | 05/27/2025 | Non-covered Recipient Entity Tandem Clinical Research-Marrero Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220716144 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $912.50 | 05/27/2025 | Non-covered Recipient Entity Tandem Clinical Research-Marrero Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220716146 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5.00 | 05/27/2025 | Non-covered Recipient Entity Tandem Clinical Research-Marrero Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220716148 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $365.00 | 05/27/2025 | Non-covered Recipient Entity Tandem Clinical Research-Marrero Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220716216 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5.00 | 05/27/2025 | Non-covered Recipient Entity Tandem Clinical Research-Marrero Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220716218 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $5,267.23 | 05/26/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192123549 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,527.46 | 05/23/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248244429 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,238.86 | 05/22/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248244232 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $8,504.26 | 05/15/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248243736 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,235.25 | 05/15/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248243740 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $8,369.50 | 05/15/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184194981 |
| Principal investigator 1 | PFIZER INC. | $2,500.00 | 05/10/2025 | Non-covered Recipient Entity Tandem Clinical Research GI LLC | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY SAFETY AND TOLERABILITY OF PONSEGROMAB IN PATIENTS WITH CANCER CACHEXIA AND ELEVATED CONCENTRATIONS OF GDF15 FOLLOWED BY AN OPTIONAL OPENLABEL TREATMENT PERIOD | No dispute reported | 06/30/2026 | 1228772454 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $86.80 | 05/09/2025 | Non-covered Recipient Individual | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults with Celiac Disease While Undergoing Oral Gluten Exposure | No dispute reported | 06/30/2026 | 1244045516 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $20.44 | 05/09/2025 | Non-covered Recipient Individual | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults with Celiac Disease While Undergoing Oral Gluten Exposure | No dispute reported | 06/30/2026 | 1244045518 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $9.11 | 05/09/2025 | Non-covered Recipient Individual | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults with Celiac Disease While Undergoing Oral Gluten Exposure | No dispute reported | 06/30/2026 | 1244045520 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $42.70 | 05/09/2025 | Non-covered Recipient Individual | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults with Celiac Disease While Undergoing Oral Gluten Exposure | No dispute reported | 06/30/2026 | 1244045522 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,437.75 | 04/28/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248242770 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,435.80 | 04/28/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184190629 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $208.00 | 04/28/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184190631 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,238.89 | 04/24/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248242609 |
| Principal investigator 1 | Senseonics, Incorporated | $2,267.81 | 04/24/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI, LLC | Senseonics CTP-0039 | No dispute reported | 06/30/2026 | 1249852945 |
| Principal investigator 1 | Senseonics, Incorporated | $2,267.81 | 04/24/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI, LLC | Senseonics CTP-0039 | No dispute reported | 06/30/2026 | 1249852947 |
| Principal investigator 1 | Senseonics, Incorporated | $2,267.81 | 04/24/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI, LLC | Senseonics CTP-0039 | No dispute reported | 06/30/2026 | 1249852949 |
| Principal investigator 1 | Senseonics, Incorporated | $87.75 | 04/24/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI, LLC | Senseonics CTP-0039 | No dispute reported | 06/30/2026 | 1249852951 |
| Principal investigator 1 | Senseonics, Incorporated | $87.75 | 04/24/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI, LLC | Senseonics CTP-0039 | No dispute reported | 06/30/2026 | 1249852953 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $4,515.75 | 04/23/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248242555 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,000.00 | 04/17/2025 | Non-covered Recipient Entity Tandem Clinical Research-Marrero Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220716206 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,500.00 | 04/17/2025 | Non-covered Recipient Entity Tandem Clinical Research-Marrero Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220716208 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,000.00 | 04/17/2025 | Non-covered Recipient Entity Tandem Clinical Research-Marrero Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220716210 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11,000.00 | 04/17/2025 | Non-covered Recipient Entity Tandem Clinical Research-Marrero Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220716212 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,000.00 | 04/17/2025 | Non-covered Recipient Entity Tandem Clinical Research-Marrero Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220716214 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,316.90 | 04/10/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192129728 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,917.89 | 04/08/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248241794 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,184.75 | 04/08/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184181918 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $135.00 | 04/04/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192129740 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $67.50 | 04/04/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192129753 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $270.00 | 04/04/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192135122 |
| Principal investigator 1 | Senseonics, Incorporated | $87.75 | 04/03/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI, LLC | Senseonics CTP-0039 | No dispute reported | 06/30/2026 | 1249852929 |
| Principal investigator 1 | Senseonics, Incorporated | $87.75 | 04/03/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI, LLC | Senseonics CTP-0039 | No dispute reported | 06/30/2026 | 1249852931 |
| Principal investigator 1 | Senseonics, Incorporated | $87.75 | 04/03/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI, LLC | Senseonics CTP-0039 | No dispute reported | 06/30/2026 | 1249852933 |
| Principal investigator 1 | Senseonics, Incorporated | $87.75 | 04/03/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI, LLC | Senseonics CTP-0039 | No dispute reported | 06/30/2026 | 1249852935 |
| Principal investigator 1 | Senseonics, Incorporated | $87.75 | 04/03/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI, LLC | Senseonics CTP-0039 | No dispute reported | 06/30/2026 | 1249852937 |
| Principal investigator 1 | Senseonics, Incorporated | $87.75 | 04/03/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI, LLC | Senseonics CTP-0039 | No dispute reported | 06/30/2026 | 1249852939 |
| Principal investigator 1 | Senseonics, Incorporated | $87.75 | 04/03/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI, LLC | Senseonics CTP-0039 | No dispute reported | 06/30/2026 | 1249852941 |
| Principal investigator 1 | Senseonics, Incorporated | $87.75 | 04/03/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI, LLC | Senseonics CTP-0039 | No dispute reported | 06/30/2026 | 1249852943 |
| Principal investigator 1 | Janssen Research & Development, LLC | $445.00 | 04/01/2025 | Non-covered Recipient Entity Tandem Intermediate Llc | A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) | No dispute reported | 06/30/2026 | 1175223879 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,500.00 | 04/01/2025 | Non-covered Recipient Entity Tandem Intermediate Llc | A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) | No dispute reported | 06/30/2026 | 1175223985 |
| Principal investigator 1 | Janssen Research & Development, LLC | $248.00 | 04/01/2025 | Non-covered Recipient Entity Tandem Intermediate Llc | A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) | No dispute reported | 06/30/2026 | 1175224010 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $100.00 | 04/01/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248241486 |
| Principal investigator 1 | Senseonics, Incorporated | $2,267.81 | 03/27/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI, LLC | Senseonics CTP-0039 | No dispute reported | 06/30/2026 | 1249852921 |
| Principal investigator 1 | Senseonics, Incorporated | $2,317.81 | 03/27/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI, LLC | Senseonics CTP-0039 | No dispute reported | 06/30/2026 | 1249852923 |
| Principal investigator 1 | Senseonics, Incorporated | $87.75 | 03/27/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI, LLC | Senseonics CTP-0039 | No dispute reported | 06/30/2026 | 1249852925 |
| Principal investigator 1 | Senseonics, Incorporated | $2,317.81 | 03/27/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI, LLC | Senseonics CTP-0039 | No dispute reported | 06/30/2026 | 1249852927 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $279.84 | 03/25/2025 | Non-covered Recipient Entity Tandem Clinical Research-Marrero Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220716134 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $159.84 | 03/25/2025 | Non-covered Recipient Entity Tandem Clinical Research-Marrero Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220716136 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,058.50 | 03/25/2025 | Non-covered Recipient Entity Tandem Clinical Research-Marrero Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220716138 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $16.00 | 03/25/2025 | Non-covered Recipient Entity Tandem Clinical Research-Marrero Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220716140 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $9,844.47 | 03/21/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192129716 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,500.00 | 03/20/2025 | Non-covered Recipient Entity Tandem Clinic Rsrch Gi Llc | A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) | No dispute reported | 06/30/2026 | 1175223886 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,500.00 | 03/19/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | THE STUDY EXPLORES THE MECHANISM OF ACTION AND EVALUATES THE SAFETY OF ONTAMALIMAB IN PARTICIPANTS WITH NONALCOHOLIC STEATOHEPATITIS WITH FIBROSIS STAGES 2 THROUGH 4 | No dispute reported | 06/30/2026 | 1223276775 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,500.00 | 03/19/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | THE STUDY EXPLORES THE MECHANISM OF ACTION AND EVALUATES THE SAFETY OF ONTAMALIMAB IN PARTICIPANTS WITH NONALCOHOLIC STEATOHEPATITIS WITH FIBROSIS STAGES 2 THROUGH 4 | No dispute reported | 06/30/2026 | 1223276777 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,200.00 | 03/19/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | THE STUDY EXPLORES THE MECHANISM OF ACTION AND EVALUATES THE SAFETY OF ONTAMALIMAB IN PARTICIPANTS WITH NONALCOHOLIC STEATOHEPATITIS WITH FIBROSIS STAGES 2 THROUGH 4 | No dispute reported | 06/30/2026 | 1223276779 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $135.00 | 03/17/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192127773 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $405.00 | 03/17/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192138483 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $20,332.60 | 03/17/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248241032 |
| Principal investigator 1 | Senseonics, Incorporated | $87.75 | 03/13/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI, LLC | Senseonics CTP-0039 | No dispute reported | 06/30/2026 | 1249852917 |
| Principal investigator 1 | Bausch Health US, LLC | $965.08 | 03/11/2025 | Non-covered Recipient Entity Tandem Clinical Research GI, LLC | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis | No dispute reported | 06/30/2026 | 1224846249 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,000.00 | 03/06/2025 | Non-covered Recipient Entity Tandem Clinical Research-Marrero Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220716114 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,000.00 | 03/06/2025 | Non-covered Recipient Entity Tandem Clinical Research-Marrero Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220716116 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11,000.00 | 03/06/2025 | Non-covered Recipient Entity Tandem Clinical Research-Marrero Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220716118 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,000.00 | 03/06/2025 | Non-covered Recipient Entity Tandem Clinical Research-Marrero Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220716120 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,500.00 | 03/06/2025 | Non-covered Recipient Entity Tandem Clinical Research-Marrero Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220716122 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $3,567.20 | 03/06/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248240580 |
| Principal investigator 1 | Senseonics, Incorporated | $2,317.81 | 03/06/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI, LLC | Senseonics CTP-0039 | No dispute reported | 06/30/2026 | 1249852919 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2.14 | 02/28/2025 | Non-covered Recipient Entity Tandem Clinical Research-Marrero Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220716098 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $12.86 | 02/28/2025 | Non-covered Recipient Entity Tandem Clinical Research-Marrero Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220716100 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $239.89 | 02/28/2025 | Non-covered Recipient Entity Tandem Clinical Research-Marrero Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220716102 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5.52 | 02/28/2025 | Non-covered Recipient Entity Tandem Clinical Research-Marrero Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220716104 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.50 | 02/28/2025 | Non-covered Recipient Entity Tandem Clinical Research-Marrero Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220716106 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.50 | 02/28/2025 | Non-covered Recipient Entity Tandem Clinical Research-Marrero Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220716108 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $21.43 | 02/28/2025 | Non-covered Recipient Entity Tandem Clinical Research-Marrero Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220716110 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $33.71 | 02/28/2025 | Non-covered Recipient Entity Tandem Clinical Research-Marrero Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220716112 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $151.58 | 02/25/2025 | Non-covered Recipient Entity Tandem Clinical Research-Marrero Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220716124 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $139.86 | 02/25/2025 | Non-covered Recipient Entity Tandem Clinical Research-Marrero Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220716126 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $620.50 | 02/25/2025 | Non-covered Recipient Entity Tandem Clinical Research-Marrero Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220716128 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.08 | 02/25/2025 | Non-covered Recipient Entity Tandem Clinical Research-Marrero Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220716130 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5.00 | 02/25/2025 | Non-covered Recipient Entity Tandem Clinical Research-Marrero Clinic | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220716132 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $151.58 | 02/25/2025 | Non-covered Recipient Entity Tandem Clinical Research-Marrero Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220716196 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $139.86 | 02/25/2025 | Non-covered Recipient Entity Tandem Clinical Research-Marrero Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220716198 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $620.50 | 02/25/2025 | Non-covered Recipient Entity Tandem Clinical Research-Marrero Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220716200 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.08 | 02/25/2025 | Non-covered Recipient Entity Tandem Clinical Research-Marrero Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220716202 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5.00 | 02/25/2025 | Non-covered Recipient Entity Tandem Clinical Research-Marrero Clinic | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220716204 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,435.80 | 02/25/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184155564 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,000.00 | 02/25/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184155566 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,057.30 | 02/25/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | THE STUDY EXPLORES THE MECHANISM OF ACTION AND EVALUATES THE SAFETY OF ONTAMALIMAB IN PARTICIPANTS WITH NONALCOHOLIC STEATOHEPATITIS WITH FIBROSIS STAGES 2 THROUGH 4 | No dispute reported | 06/30/2026 | 1223275517 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,769.62 | 02/24/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192127767 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,467.00 | 02/24/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA | No dispute reported | 06/30/2026 | 1192135115 |
| Principal investigator 1 | Janssen Research & Development, LLC | $477.00 | 02/19/2025 | Non-covered Recipient Entity Tandem Clinic Rsrch Gi Llc | A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) | No dispute reported | 06/30/2026 | 1175223948 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $200.00 | 02/18/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184154510 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6,290.00 | 02/18/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184154648 |
| Principal investigator 1 | Senseonics, Incorporated | $2,317.81 | 02/13/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI, LLC | Senseonics CTP-0039 | No dispute reported | 06/30/2026 | 1249852915 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,392.07 | 02/06/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248239395 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $27,918.01 | 02/06/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248239399 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $212.00 | 01/29/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | THE STUDY EXPLORES THE MECHANISM OF ACTION AND EVALUATES THE SAFETY OF ONTAMALIMAB IN PARTICIPANTS WITH NONALCOHOLIC STEATOHEPATITIS WITH FIBROSIS STAGES 2 THROUGH 4 | No dispute reported | 06/30/2026 | 1223274523 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,274.00 | 01/28/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA | No dispute reported | 06/30/2026 | 1192127746 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,555.00 | 01/28/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA | No dispute reported | 06/30/2026 | 1192129722 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $11,273.17 | 01/28/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192135084 |
| Principal investigator 1 | Janssen Research & Development, LLC | $236.00 | 01/27/2025 | Non-covered Recipient Entity Tandem Clinic Rsrch Gi Llc | A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) | No dispute reported | 06/30/2026 | 1175224099 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,435.80 | 01/21/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184149184 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,483.00 | 01/21/2025 | Non-covered Recipient Entity TANDEM INTERMEDIATE LLC | A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD | No dispute reported | 06/30/2026 | 1184149186 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,250.00 | 01/21/2025 | Non-covered Recipient Entity TANDEM INTERMEDIATE LLC | A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD | No dispute reported | 06/30/2026 | 1184149188 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $9,900.00 | 01/21/2025 | Non-covered Recipient Entity TANDEM INTERMEDIATE LLC | A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD | No dispute reported | 06/30/2026 | 1184149190 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,732.00 | 01/21/2025 | Non-covered Recipient Entity TANDEM INTERMEDIATE LLC | A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD | No dispute reported | 06/30/2026 | 1184149192 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,435.80 | 01/17/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184148289 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $7,290.00 | 01/17/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184148291 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $650.00 | 01/17/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184148293 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $537.50 | 01/17/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184148297 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $500.00 | 01/17/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184148299 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $500.00 | 01/17/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184148301 |
| Principal investigator 1 | Senseonics, Incorporated | $2,317.81 | 01/16/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI, LLC | Senseonics CTP-0039 | No dispute reported | 06/30/2026 | 1249852909 |
| Principal investigator 1 | Senseonics, Incorporated | $2,317.81 | 01/16/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI, LLC | Senseonics CTP-0039 | No dispute reported | 06/30/2026 | 1249852911 |
| Principal investigator 1 | Senseonics, Incorporated | $2,317.81 | 01/16/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI, LLC | Senseonics CTP-0039 | No dispute reported | 06/30/2026 | 1249852913 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,873.13 | 01/09/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248238273 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,660.64 | 01/09/2025 | Non-covered Recipient Entity TANDEM INTERMEDIATE LLC | A Two-Part, Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-PNP, an siRNA Targeting PNPLA3, in Healthy Adults and Adult Participants With NAFLD | No dispute reported | 06/30/2026 | 1184147373 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,000.00 | 01/09/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | THE STUDY EXPLORES THE MECHANISM OF ACTION AND EVALUATES THE SAFETY OF ONTAMALIMAB IN PARTICIPANTS WITH NONALCOHOLIC STEATOHEPATITIS WITH FIBROSIS STAGES 2 THROUGH 4 | No dispute reported | 06/30/2026 | 1223273833 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,500.00 | 01/09/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | THE STUDY EXPLORES THE MECHANISM OF ACTION AND EVALUATES THE SAFETY OF ONTAMALIMAB IN PARTICIPANTS WITH NONALCOHOLIC STEATOHEPATITIS WITH FIBROSIS STAGES 2 THROUGH 4 | No dispute reported | 06/30/2026 | 1223273835 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,000.00 | 01/09/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | THE STUDY EXPLORES THE MECHANISM OF ACTION AND EVALUATES THE SAFETY OF ONTAMALIMAB IN PARTICIPANTS WITH NONALCOHOLIC STEATOHEPATITIS WITH FIBROSIS STAGES 2 THROUGH 4 | No dispute reported | 06/30/2026 | 1223273837 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,723.90 | 01/07/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | THE STUDY EXPLORES THE MECHANISM OF ACTION AND EVALUATES THE SAFETY OF ONTAMALIMAB IN PARTICIPANTS WITH NONALCOHOLIC STEATOHEPATITIS WITH FIBROSIS STAGES 2 THROUGH 4 | No dispute reported | 06/30/2026 | 1223273615 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,238.89 | 01/06/2025 | Non-covered Recipient Entity TANDEM CLINICAL RESEARCH GI LLC | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248238056 |
Ownership and Investment Interests
One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together
| Program year | Measure | Amount | Records |
|---|---|---|---|
| PY2024 | Amount invested | $0.00 | 1 |
| PY2024 | Value of interest | $8,195.02 | 1 |
| PY2023 | Amount invested | $0.00 | 1 |
| PY2023 | Value of interest | $8,195.02 | 1 |
| PY2022 | Amount invested | $0.00 | 1 |
| PY2022 | Value of interest | $519.09 | 1 |
| PY2021 | Amount invested | $435.44 | 1 |
| PY2021 | Value of interest | $544.45 | 1 |
Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.
Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.
Ownership and Investment Interests records
Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them
4 records · PY2021–2024
| Program year | Company | Amount invested | Value of interest | Terms of interest | Interest held by | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| PY2024 | GastroGPO, LLC | $0.00 | $8,195.02 | Common Stock | Physician Covered Recipient | No dispute reported | 06/30/2026 | 1124820124 |
| PY2023 | GastroGPO, LLC | $0.00 | $8,195.02 | Common Stock | Physician Covered Recipient | No dispute reported | 06/30/2026 | 1050730553 |
| PY2022 | GastroGPO, LLC | $0.00 | $519.09 | Common Stock | Physician Covered Recipient | No dispute reported | 06/30/2026 | 955001039 |
| PY2021 | GastroGPO, LLC | $435.44 | $544.45 | Common Stock | Physician Covered Recipient | No dispute reported | 06/30/2026 | 854914441 |